Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Heat shock protein family B (small) member 7 (HSPB7) is a muscle-specific molecular chaperone, predominantly expressed in the heart, belonging to the small heat shock protein family. Functionally, HSPB7 stabilizes sarcomeric structure and organizes actin filaments, modulates protein homeostasis, and has both chaperone and redox regulatory activity. It prevents aggregation of large cytoskeletal proteins (e.g., filamin C, titin) and plays a central role in maintaining cardiovascular integrity. Genetic mutations or deficiency in HSPB7 lead to severe cardiac defects, arrhythmias, and heart failure, and the protein is often inactivated or lost in diverse cancers, where it can act as a tumor suppressor. HSPB7 is also under investigation as a potential biomarker of cardiac disease and injury. There are currently no known direct-acting pharmacological inhibitors or modulators of HSPB7.
No pharmacological drugs are currently known to target HSPB7 directly; its mechanisms relate to chaperone activity and actin regulation. Mechanistic studies refer to genetic manipulation or modulation of protein activity rather than drug action.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Heat shock protein family B (small) member 7 (HSPB7).